Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087358 | 0.95 | PTGER4 (0.55) | PTGER4PTGER2KMT2AMEN1KDM4E | |
| SCHEMBL4087328 | 0.94 | PTGER4 (0.44) | PTGER4PTGER2HDAC1HDAC8KMT2A | |
| SCHEMBL4086039 | 0.88 | PTGER4 (0.42) | PTGER4PTGER2HDAC1HDAC8KMT2A | |
| SCHEMBL4085409 | 0.88 | PTGER4 (0.43) | PTGER4PTGER2KMT2AMEN1KDM4E | |
| SCHEMBL5575957 | 0.86 | PTGER4 (0.51) | PTGER4PTGER2HDAC1HDAC8KMT2A | |
| SCHEMBL4077429 | 0.86 | PTGER4 (0.69) | PTGER4PTGER2 | |
| SCHEMBL4087532 | 0.84 | MAOB (0.44) | PTGER4PTGER2KMT2AMEN1KDM4E | |
| SCHEMBL4086064 | 0.82 | PTGER4 (0.47) | PTGER4PTGER2KMT2AMEN1 | |
| SCHEMBL4084927 | 0.82 | PTGER4 (0.42) | PTGER4PTGER2KMT2AMEN1KDM4E | |
| SCHEMBL27717957 | 0.81 | KMT2A (0.47) | PTGER4PTGER2KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | PTGER4 33/4885PTGER2 39/4885HDAC1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.